BCL10 Antibody, KO Validated | 13-898

BCL10 Antibody, KO Validated | 13-898 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-233 of human BCL10 (NP_003912.1) .

Research Area: Apoptosis, Cancer, Cell Cycle, Immunology, Signal Transduction

Tested Application: WB

Application: WB: 1:500 - 1:2000

Specificiy: N/A

Positive Control 1: MCF-7

Positive Control 2: DU145

Positive Control 3: A-549

Positive Control 4: BT-474

Positive Control 5: Jurkat

Positive Control 6: N/A

Molecular Weight: Observed: 33kDa

Validation: Antibody is Knockout validated.

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: Bcl-10 Antibody: CLAP, mE10, CIPER, c-E10, CARMEN, CLAP, CARD-containing molecule enhancing NF-kappa-B, Bcl-10

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD) , and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. Alternative splicing results in multiple transcript variants.